TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+24.49%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.63B
AUM Growth
+$2.63B
(+19%)
Cap. Flow
+$15.5M
Cap. Flow
% of AUM
0.59%
Top 10 Holdings %
Top 10 Hldgs %
37.9%
Holding
228
New
11
Increased
46
Reduced
32
Closed
6
Top Buys
| 1 |
AbbVie
ABBV
|
$18.9M |
| 2 |
UnitedHealth
UNH
|
$15.7M |
| 3 |
Moderna
MRNA
|
$15.3M |
| 4 |
CVS Health
CVS
|
$14.4M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$10.6M |
Top Sells
| 1 |
AGN
Allergan plc
AGN
|
$28M |
| 2 |
Biogen
BIIB
|
$26.5M |
| 3 |
Gilead Sciences
GILD
|
$23.6M |
| 4 |
Illumina
ILMN
|
$18.8M |
| 5 |
Cigna
CI
|
$11.8M |
Sector Composition
| 1 | Healthcare | 95.26% |
| 2 | Real Estate | 2.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Amgen
AMGN
$155B
| $144M | 5.49% | 611,962 +12,091 | +2% | +$2.85M |
|
2
Vertex Pharmaceuticals
VRTX
$100B
| $139M | 5.27% | 477,330 -8,400 | -2% | -$2.44M |
|
|
3
Gilead Sciences
GILD
$140B
| $122M | 4.63% | 1,581,026 -307,279 | -16% | -$23.6M |
|
|
4
Regeneron Pharmaceuticals
REGN
$61.5B
| $117M | 4.46% | 187,935 +17,057 | +10% | +$10.6M |
|
5
Johnson & Johnson
JNJ
$427B
| $117M | 4.44% | 830,031 -8,738 | -1% | -$1.23M |
|
|
6
UnitedHealth
UNH
$281B
| $82.6M | 3.15% | 280,151 +53,324 | +24% | +$15.7M |
|
|
7
Illumina
ILMN
$15.8B
| $79.5M | 3.03% | 214,651 -50,668 | -19% | -$18.8M |
|
8
Merck
MRK
$210B
| $75.1M | 2.86% | 971,496 -51,100 | -5% | -$3.95M |
|
|
9
Biogen
BIIB
$19.4B
| $62.5M | 2.38% | 233,599 -99,136 | -30% | -$26.5M |
|
10
Bristol-Myers Squibb
BMY
$96B
| $57.5M | 2.19% | 977,505 +132,573 | +16% | +$7.8M |
|
11
Pfizer
PFE
$141B
| $54.2M | 2.06% | 1,656,548 -163,700 | -9% | -$5.35M |
|
|
12
AbbVie
ABBV
$372B
| $52.4M | 1.99% | 533,725 +192,809 | +57% | +$18.9M |
|
|
13
CVS Health
CVS
$92.8B
| $46.8M | 1.78% | 719,620 +221,634 | +45% | +$14.4M |
|
14
Abbott
ABT
$231B
| $44.5M | 1.69% | 486,250 +19,700 | +4% | +$1.8M |
|
15
Medtronic
MDT
$119B
| $43.6M | 1.66% | 475,489 +28,478 | +6% | +$2.61M |
|
|
ALXN
16
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $43.2M | 1.64% | 384,709 -28,617 | -7% | -$3.21M |
|
|
SGEN
17
DELISTED
Seagen Inc. Common Stock
SGEN
| $40.9M | 1.56% | 240,559 +26,029 | +12% | +$4.42M |
|
18
Thermo Fisher Scientific
TMO
$186B
| $38.4M | 1.46% | 106,025 -6,000 | -5% | -$2.17M |
|
19
Eli Lilly
LLY
$657B
| $34M | 1.29% | 206,837 -51,832 | -20% | -$8.51M |
|
20
Incyte
INCY
$16.5B
| $33.8M | 1.29% | 325,053 -107,193 | -25% | -$11.1M |
|
|
21
Moderna
MRNA
$9.37B
| $31.6M | 1.2% | 492,506 +238,360 | +94% | +$15.3M |
|
22
BioMarin Pharmaceuticals
BMRN
$11.2B
| $30.3M | 1.15% | 245,362 -25,251 | -9% | -$3.11M |
|
23
Stryker
SYK
$150B
| $29.6M | 1.13% | 164,230 +28,435 | +21% | +$5.12M |
|
24
Danaher
DHR
$147B
| $28.2M | 1.07% | 159,352 | – | – |
|
25
Neurocrine Biosciences
NBIX
$13.8B
| $25.2M | 0.96% | 206,150 | – | – |
|